
First Patient Enrolled in MAGIC Clinical Trial for Glaucoma

Adelaide, Australia, 30 April 2021 – Nova Eye Medical Limited (ASX: EYE)(Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces the enrollment of the first glaucoma patient in the **M**ulti-centre **A**b-interno **G**laucoma study **I**nvestigating **C**analoplasty (“MAGIC”) trial. MAGIC is a prospective, randomised, single-masked trial across eight surgery centres in the USA and sponsored by Nova Eye Medical.

According to the World Health Organisation, glaucoma is the world’s second leading cause of blindness, with the number of suspected cases of glaucoma estimated at over 60 million worldwide.

The first MAGIC patient was enrolled at the Eye Physicians & Surgeons of Arizona, Arizona, USA, by principal investigator Dr Shamil Patel, MD. According to Dr. Patel, the unique mechanism of ab-interno canaloplasty, which reduces outflow resistance in all parts of the natural drainage system, recommends its role in the glaucoma treatment armamentarium. Further, the ability to deploy ab-interno canaloplasty as a standalone procedure, and in combination with cataract surgery, supports its versatility in the glaucoma treatment algorithm.

The MAGIC Trial will be performed over a 12-month period and will enrol up to 160 patients with mild to moderate, uncontrolled primary open-angle glaucoma (POAG) on 1-4 medications. Patients will be randomized to treatment with either the iTrack™ canaloplasty microcatheter or the OMNI® surgical system (Sight Sciences). Ab-interno canaloplasty will be performed as a standalone procedure during the trial to eliminate the confounding effect of cataract surgery. Primary endpoints will include reduction in mean intraocular pressure (IOP) and mean number of anti-glaucoma medications. Secondary endpoints will include surgical and post-operative complications.

The MAGIC Trial is expected to reinforce the clinical utility of iTrack™ ab-interno canaloplasty in the treatment of mild-moderate glaucoma patients. The Company anticipates publication of the completed 12-month results in the second half of 2022.

Further information on the MAGIC Trial can be found via the links below:

- <https://glaucoma-itrack.com/magic>
- <https://clinicaltrials.gov> (NCT04769453)

This release dated 30 April 2021 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.

– ENDS –

Company

Tom Spurling
Director
Nova Eye Medical Limited
W +61 417 818 658
tspurling@nova-eye.com

Investors

Dr. Tom Duthy
Investor Relations & Corporate Development
Nova Eye Medical Limited
W +61 402 493 727
tduthy@nova-eye.com

Media

Kate Hunt
Head of Marketing
Nova Eye Medical Limited
W +61 404 080 679
khunt@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com